What is Calithera Biosciences Inc's earnings per share (EPS)?

Calithera Biosciences Inc (CALA) reported diluted earnings per share of $-7.94 for fiscal year 2022. This represents a 74.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Calithera Biosciences Inc Financials

CALA

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2022 Currency USD FYE December

This page shows Calithera Biosciences Inc (CALA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CALA FY2022 2026-04-22

Calithera had become a cash-funded R&D platform, with operating burn rather than asset investment driving balance-sheet change.

From FY2020 to FY2022, cash reserves fell from $107.1M to $25.5M. Even after R&D spend was cut to $28.5M, FY2022 operating cash burn remained -$43.6M, showing that program cuts slowed the drain but did not create a self-funding business.

Earnings quality was fairly direct: FY2022 net loss of -$39.7M sat close to operating cash outflow of -$43.6M, so the loss was backed by real cash use rather than accounting noise. Because capital intensity was tiny, with capex of just $133K, free cash flow stayed near operating cash flow; this company was spending to run research programs, not to build physical capacity.

Liquidity looked better than the headline losses imply: cash of $25.5M still exceeded total liabilities of $8.3M, and no long-term debt was reported. But the real pressure point was runway, not solvency, because the balance sheet had to absorb another year of more than $40M in operating cash use even after the FY2021 liability bulge receded.

Financial Health Signals

Financial Profile 27/100

Based on FY2022 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →

Health score ≠ stock price. This rates the quality of Calithera Biosciences Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Leverage

Calithera Biosciences Inc carries a low D/E ratio of 0.41, meaning only $0.41 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

With a current ratio of 3.60, Calithera Biosciences Inc holds $3.60 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.

Returns

Calithera Biosciences Inc generates a -194.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -1373.0% the prior year.

Piotroski F-Score Weak

1/9

Calithera Biosciences Inc passes 1 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).

Earnings Quality Low Quality

1.10x

For every $1 of reported earnings, Calithera Biosciences Inc generates $1.10 in operating cash flow (-$43.6M OCF vs -$39.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$41.8M

YoY+63.7%

Calithera Biosciences Inc's EBITDA was -$41.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 63.7% from the prior year.

Net Income

-$39.6M

YoY+65.5%

Calithera Biosciences Inc reported -$39.6M in net income in fiscal year 2022. This represents an increase of 65.5% from the prior year.

EPS (Diluted)

$-7.94

YoY+74.5%

Calithera Biosciences Inc earned $-7.94 per diluted share (EPS) in fiscal year 2022. This represents an increase of 74.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$43.7M

YoY+34.2%

Calithera Biosciences Inc generated -$43.7M in free cash flow in fiscal year 2022, representing cash available after capex. This represents an increase of 34.2% from the prior year.

Cash & Debt

$25.5M

YoY-57.3%

5Y CAGR-12.1%

10Y CAGR+27.7%

Calithera Biosciences Inc held $25.5M in cash against $0 in long-term debt as of fiscal year 2022.

Dividends Per Share

N/A

Shares Outstanding

YoY+26.2%

Calithera Biosciences Inc had 5M shares outstanding in fiscal year 2022. This represents an increase of 26.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-194.4%

YoY+1178.6pp

5Y CAGR-175.9pp

Calithera Biosciences Inc's ROE was -194.4% in fiscal year 2022, measuring profit generated per dollar of shareholder equity. This is up 1178.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$28.5M

YoY-46.6%

5Y CAGR-7.9%

10Y CAGR+15.8%

Calithera Biosciences Inc invested $28.5M in research and development in fiscal year 2022. This represents a decrease of 46.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$133K

YoY-9.5%

5Y CAGR-35.9%

10Y CAGR+10.5%

Calithera Biosciences Inc invested $133K in capex in fiscal year 2022, funding long-term assets and infrastructure. This represents a decrease of 9.5% from the prior year.

CALA Income Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Revenue	N/A	$9.8M	N/A	N/A	$22.3M-14.3%	$26.0M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$28.5M-46.6%	$53.5M-24.7%	$71.0M-6.9%	$76.3M+15.3%	$66.2M+53.5%	$43.1M
SG&A Expenses	$13.5M-35.1%	$20.9M+2.4%	$20.4M+22.7%	$16.6M+24.5%	$13.3M+6.5%	$12.5M
Operating Income	-$42.1M+63.6%	-$115.4M-26.3%	-$91.4M+1.6%	-$92.9M-62.2%	-$57.3M-93.0%	-$29.7M
Interest Expense	N/A	N/A	N/A	N/A	$2.7M+42.6%	$1.9M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$39.6M+65.5%	-$115.1M-27.7%	-$90.1M-0.3%	-$89.9M-64.5%	-$54.6M-96.3%	-$27.8M
EPS (Diluted)	$-7.94+74.5%	$-31.16	$-26.20	N/A	N/A	N/A

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Revenue	N/A	N/A	N/A	N/A	N/A	$6.8M+125.0%	$3.0M	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	$6.4M-16.9%	$7.8M-18.9%	$9.6M	N/A	$11.6M-9.9%	$12.8M-16.4%	$15.3M
SG&A Expenses	N/A	$3.1M-14.9%	$3.6M-15.1%	$4.3M	N/A	$6.3M+41.4%	$4.5M-17.3%	$5.4M
Operating Income	N/A	-$9.5M+16.3%	-$11.4M+17.7%	-$13.8M	N/A	-$11.2M+22.1%	-$14.3M+31.1%	-$20.8M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	-$9.8M-8.0%	-$9.1M+34.4%	-$13.8M	N/A	-$11.2M+21.9%	-$14.3M+29.8%	-$20.4M
EPS (Diluted)	N/A	$-2.01-26.4%	$-1.59	N/A	N/A	$-3.01+22.0%	$-3.86	N/A

CALA Balance Sheet

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Total Assets	$28.7M-55.7%	$64.8M-48.4%	$125.6M-25.6%	$168.8M+18.2%	$142.7M-25.8%	$192.5M
Current Assets	$26.6M-56.7%	$61.5M-48.2%	$118.7M-25.7%	$159.8M+13.9%	$140.3M-16.4%	$167.7M
Cash & Equivalents	$25.5M-57.3%	$59.5M-44.4%	$107.1M+77.3%	$60.4M+18.4%	$51.1M+5.3%	$48.5M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	$1.5M+219.7%	$482K-75.9%	$2.0M+74.9%	$1.1M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.3M-85.3%	$56.4M+142.8%	$23.2M-11.9%	$26.3M+64.5%	$16.0M-62.0%	$42.1M
Current Liabilities	$7.4M-47.2%	$14.0M-23.9%	$18.4M-6.2%	$19.6M+31.9%	$14.9M-61.9%	$39.0M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$20.4M+143.3%	$8.4M-91.8%	$102.4M-28.1%	$142.4M+12.4%	$126.7M-15.7%	$150.3M
Retained Earnings	-$512.6M-4.3%	-$491.3M-30.6%	-$376.2M-31.5%	-$286.1M-45.8%	-$196.2M-30.5%	-$150.3M

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Total Assets	$28.7M-22.7%	$37.1M-18.6%	$45.6M-9.3%	$50.2M-22.4%	$64.8M-28.0%	$90.0M-8.1%	$97.9M-11.6%	$110.7M
Current Assets	$26.6M-23.3%	$34.7M-19.0%	$42.8M-9.4%	$47.3M-23.1%	$61.5M-28.8%	$86.3M-8.1%	$94.0M-11.8%	$106.5M
Cash & Equivalents	$25.5M-25.3%	$34.1M-18.5%	$41.8M-6.4%	$44.7M-25.0%	$59.5M-29.5%	$84.5M-8.4%	$92.2M-9.0%	$101.4M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	$12K0.0%	$12K-98.8%	$1.0M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$8.3M-22.5%	$10.7M+3.8%	$10.3M-80.7%	$53.4M-5.3%	$56.4M+262.5%	$15.6M+4.8%	$14.8M-10.0%	$16.5M
Current Liabilities	$7.4M-20.0%	$9.2M+3.8%	$8.9M-21.8%	$11.4M-18.8%	$14.0M+3.5%	$13.5M+8.4%	$12.5M-9.5%	$13.8M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$20.4M-22.7%	$26.4M-25.1%	$35.3M+1224.1%	-$3.1M-137.4%	$8.4M-88.7%	$74.4M-10.4%	$83.0M-11.8%	$94.2M
Retained Earnings	-$512.6M-1.4%	-$505.7M-2.0%	-$495.9M+1.8%	-$505.2M-2.8%	-$491.3M-16.4%	-$422.1M-2.7%	-$410.9M-3.6%	-$396.6M

CALA Cash Flow Statement

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Operating Cash Flow	-$43.6M+34.2%	-$66.3M+21.4%	-$84.3M-7.1%	-$78.7M-21.4%	-$64.8M-571.5%	$13.8M
Capital Expenditures	$133K-9.5%	$147K+141.0%	$61K+771.4%	$7K-96.7%	$214K-82.6%	$1.2M
Free Cash Flow	-$43.7M+34.2%	-$66.4M+21.2%	-$84.4M-7.1%	-$78.8M-21.1%	-$65.1M-619.5%	$12.5M
Investing Cash Flow	-$133K-101.7%	$7.9M-91.2%	$89.0M+924.9%	-$10.8M-120.4%	$52.8M+153.6%	-$98.4M
Financing Cash Flow	$9.7M-9.5%	$10.7M-74.6%	$42.1M-57.5%	$98.9M+576.2%	$14.6M-88.1%	$122.9M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Operating Cash Flow	-$8.6M-11.1%	-$7.7M+31.3%	-$11.3M+29.6%	-$16.0M+37.4%	-$25.6M-236.3%	-$7.6M+31.6%	-$11.1M+49.5%	-$22.0M
Capital Expenditures	$23K	$0	N/A	N/A	$39K	N/A	N/A	N/A
Free Cash Flow	-$8.6M-11.4%	-$7.7M	N/A	N/A	-$25.6M	N/A	N/A	N/A
Investing Cash Flow	-$23K	$0	N/A	N/A	-$39K+63.9%	-$108K-107.2%	$1.5M-76.9%	$6.5M
Financing Cash Flow	$4K-73.3%	$15K-99.8%	$8.5M+647.5%	$1.1M+73.6%	$655K+65400.0%	$1K-99.8%	$475K-95.0%	$9.5M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

CALA Financial Ratios

Metric	FY22	FY21	FY20	FY19	FY18	FY17
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	-1183.9%	N/A	N/A	-257.4%-143.0pp	-114.4%
Net Margin	N/A	-1180.4%	N/A	N/A	-245.5%-138.3pp	-107.2%
Return on Equity	-194.4%+1178.6pp	-1373.0%-1285.0pp	-88.0%-25.0pp	-63.1%-20.0pp	-43.1%-24.6pp	-18.5%
Return on Assets	-138.3%+39.5pp	-177.7%-106.0pp	-71.8%-18.5pp	-53.2%-15.0pp	-38.3%-23.8pp	-14.5%
Current Ratio	3.60-0.8	4.39-2.1	6.45-1.7	8.14-1.3	9.42+5.1	4.30
Debt-to-Equity	0.41-6.3	6.73+6.5	0.23+0.0	0.18+0.1	0.13-0.2	0.28
FCF Margin	N/A	-681.5%	N/A	N/A	-292.3%-340.6pp	48.3%

Metric	Q4'22	Q3'22	Q2'22	Q1'22	Q4'21	Q3'21	Q2'21	Q1'21
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	-165.2%+311.7pp	-476.9%	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	-165.5%+311.5pp	-477.0%	N/A
Return on Equity	N/A	-37.1%-11.4pp	-25.8%	N/A	N/A	-15.0%+2.2pp	-17.2%+4.4pp	-21.7%
Return on Assets	N/A	-26.4%-6.5pp	-19.9%+7.6pp	-27.5%	N/A	-12.4%+2.2pp	-14.6%+3.8pp	-18.4%
Current Ratio	3.60-0.2	3.76-1.1	4.81+0.7	4.16-0.2	4.39-2.0	6.38-1.2	7.53-0.2	7.72
Debt-to-Equity	0.410.0	0.41+0.1	0.29+17.3	-17.02-23.7	6.73+6.5	0.21+0.0	0.180.0	0.18
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Zhejiang Dashang Media TKVR

$16K

Better For You Wellness Inc BFYW

$51K

DRAZCANNA INC DZCA

$50K

Methes Energies MEIL

$10K

Monkey Rock Group Inc MKRO

$70K

Frequently Asked Questions

Is Calithera Biosciences Inc profitable?

No, Calithera Biosciences Inc (CALA) reported a net income of -$39.6M in fiscal year 2022.

What is Calithera Biosciences Inc's EBITDA?

Calithera Biosciences Inc (CALA) had EBITDA of -$41.8M in fiscal year 2022, measuring earnings before interest, taxes, depreciation, and amortization.

What is Calithera Biosciences Inc's return on equity (ROE)?

Calithera Biosciences Inc (CALA) has a return on equity of -194.4% for fiscal year 2022, measuring how efficiently the company generates profit from shareholder equity.

What is Calithera Biosciences Inc's free cash flow?

Calithera Biosciences Inc (CALA) generated -$43.7M in free cash flow during fiscal year 2022. This represents a 34.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Calithera Biosciences Inc's operating cash flow?

Calithera Biosciences Inc (CALA) generated -$43.6M in operating cash flow during fiscal year 2022, representing cash generated from core business activities.

What are Calithera Biosciences Inc's total assets?

Calithera Biosciences Inc (CALA) had $28.7M in total assets as of fiscal year 2022, including both current and long-term assets.

What are Calithera Biosciences Inc's capital expenditures?

Calithera Biosciences Inc (CALA) invested $133K in capital expenditures during fiscal year 2022, funding long-term assets and infrastructure.

How much does Calithera Biosciences Inc spend on research and development?

Calithera Biosciences Inc (CALA) invested $28.5M in research and development during fiscal year 2022.

How many shares does Calithera Biosciences Inc have outstanding?

Calithera Biosciences Inc (CALA) had 5M shares outstanding as of fiscal year 2022.

What is Calithera Biosciences Inc's current ratio?

Calithera Biosciences Inc (CALA) had a current ratio of 3.60 as of fiscal year 2022, which is generally considered healthy.

What is Calithera Biosciences Inc's debt-to-equity ratio?

Calithera Biosciences Inc (CALA) had a debt-to-equity ratio of 0.41 as of fiscal year 2022, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Calithera Biosciences Inc's return on assets (ROA)?

Calithera Biosciences Inc (CALA) had a return on assets of -138.3% for fiscal year 2022, measuring how efficiently the company uses its assets to generate profit.

What is Calithera Biosciences Inc's cash runway?

Based on fiscal year 2022 data, Calithera Biosciences Inc (CALA) had $25.5M in cash against an annual operating cash burn of $43.6M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Calithera Biosciences Inc's Piotroski F-Score?

Calithera Biosciences Inc (CALA) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Calithera Biosciences Inc's earnings high quality?

Calithera Biosciences Inc (CALA) has an earnings quality ratio of 1.10x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Calithera Biosciences Inc?

Calithera Biosciences Inc (CALA) scores 27 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.